
· Executive Brief
Thyroid Awareness Month 2026
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Leadership signal
Recognition becomes useful when leaders inspect the real route.
The strongest use of the observance is operational. Map where questions enter, how requests move, when ownership changes, and how unresolved work becomes visible. The goal is not to make a clinical claim. It is to make the organization’s response easier to understand and manage.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Thyroid care is a high-volume testing and follow-through system
Thyroid care rarely makes headlines, yet it touches almost every primary care practice, laboratory and endocrinology service. More than 10 million thyroid function tests are carried out in England each year, most requested from primary care.[7] That volume makes thyroid care a useful test of whether a health system orders the right tests, acts on the results and keeps patients connected afterward. It also involves several departments that rarely review performance together. Laboratory, imaging, primary care and specialty leaders each see one part of the route.
The evidence shows weak points at both ends of the pathway. Some testing adds little value. In Michigan, practices with high telehealth use had 40 fewer low-value thyroid tests per 1000 Medicare beneficiaries than practices with low telehealth use.[13] At the other end, monitoring that should happen often does not, and the gap is easy to miss because nothing visibly fails. Among 5,574 pregnancies with known hypothyroidism in Catalonian primary care, TSH was evaluated in the first trimester in 3,158, or 56.65%.[8]
Specialist access adds a third pressure point. In a national U.S. panel, 28% of respondents experienced a barrier accessing a specialist, including endocrinologists, for themselves or their families in 2021.[14] Thyroid nodules add a fourth: indeterminate cytology results carry very different risks, and managing them as one group invites overtreatment.[3] Both problems are, at root, questions of triage and follow-through.
This brief adds the research behind the live page’s executive guidance. It covers testing appropriateness, nodule evaluation, referral and wait times, follow-up of abnormal results and the measures leaders need to see whether diagnosis is timely and proportionate. None of it is individual medical advice. It is a map of where the system can make thyroid care more reliable. Each section ends with an operating implication that leaders can assign to an owner and measure.
Current evidence
What the research says about testing volume, value and control
Testing strategy has real consequences for downstream workload. A Welsh laboratory study examined first-line testing of both TSH and free thyroxine to find central hypothyroidism.[15] The incidence of low free thyroxine ranged from 98 to 301 cases per 100,000 population per year depending on assay method.[15] Yet only 15 new cases of central hypothyroidism were found in two health boards, about 2 cases per 100,000 population per year.[15] The positive predictive value of a low result was 2% to 4%.[15]
That pattern matters because every abnormal result triggers work. The authors concluded that screening strategies must balance yield against the cost of investigating people with non-pathological abnormalities.[15] For executives, laboratory test menus and reflex rules are operating decisions with staffing and patient experience consequences, not only technical settings. A strategy that finds about 2 true cases per 100,000 people while flagging many more for review deserves explicit governance.[15]
Treatment monitoring shows a different gap. In a city-wide population record of 47,869 people with diagnosed hypothyroidism on levothyroxine, only 43.8% had TSH within the reference range.[7] By contrast, 90.3% of untreated individuals were within the reference range.[7] The authors noted that treatment does not return patients to the TSH and free thyroxine balance seen in euthyroid individuals.[7] That complicates the use of a single target as a quality measure.
Low-value care is measurable. A Medicare cohort of 577,928 beneficiaries attributed to 2552 primary care practices used claims-based measures of low-value services, including thyroid testing.[13] High practice-level telehealth use was associated with fewer low-value thyroid tests, while most other low-value services showed no association.[13] The finding is observational, but it shows that claims data can track thyroid testing value at the practice level. Systems can use similar measures to set a baseline before changing order sets or virtual care pathways.
Subclinical results also deserve a measured response. In a Mexican public hospital endocrinology clinic, 71.2% of patients with subclinical hypothyroidism regressed to euthyroidism after three months, and 7.6% progressed to overt disease.[12] The authors described their findings as supporting a monitoring-first approach.[12] Progression was highest, at 16.0%, among patients whose initial TSH was above 6.0 and at or below 8.0 mIU/L.[12] Pathways that schedule a reliable repeat test may prevent both overtreatment and lost follow-up.
Figure 1
Thyroid care often stalls at monitoring and follow-through
Percent of patients or referrals completing a pathway step, as reported in each study. Values are copied from the cited studies [5], [7], [8], [9]; none is estimated.
Data note. These values come from different countries, years, populations and pathway steps, so this is an indirect comparison; the bars show where follow-through is incomplete, not how one step compares with another.
Limitation. Each value reflects its own setting and denominator; reference range attainment on treatment is an imperfect quality measure.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Referred primary care patients who attended a tertiary appointment | 76% | Seven primary care clinics in Singapore, 2023; 210,839 referrals | [5] |
| Pregnant women with known hypothyroidism who had first-trimester TSH testing | 56.65% | 3,158 of 5,574 pregnancies in primary care in Catalonia, 2014 to 2016 | [8] |
| Patients with hyperthyroidism retested within 2 to 6 weeks | 52.4% | 143 patients in 11 Malaysian primary care clinics, 2023 | [9] |
| Patients on levothyroxine with TSH in the reference range | 43.8% | 47,869 people with diagnosed hypothyroidism in a city-wide record in England | [7] |
| Patients with hyperthyroidism with documented treatment counseling | 28.7% | Same 143-patient Malaysian primary care sample | [9] |

Continuum of care
Where thyroid care breaks between result, action and follow-up
The continuum in thyroid care is mostly a chain of tests and decisions spread over months. A result is ordered, reported, reviewed, acted on and repeated. Each link has an owner, and each link can fail quietly. The most common failure is not a wrong decision but a decision that is never revisited. A result reviewed once and filed may not be seen again until symptoms return.
Pregnancy is the clearest example of a time-sensitive handoff. Among 111,811 pregnancies registered in primary care in Catalonia, 5,574 involved known hypothyroidism.[8] Of those tested in the first trimester, 36.3% had TSH within the recommended range and 62% were high abnormal.[8] The authors concluded that management during the first trimester needs improvement, a gap that sits between prenatal, primary care and laboratory workflows.[8]
Hyperthyroidism follow-up shows similar seams. In a review of 143 patients with overt hyperthyroidism across 11 Malaysian primary care clinics, 96.5% were correctly diagnosed.[9] Yet only 52.4% had repeat thyroid function testing within 2 to 6 weeks.[9] Within 18 months, 59.4% achieved euthyroidism and 62.2% avoided iatrogenic hypothyroidism.[9] The authors pointed to gaps in monitoring, documentation and referrals, and called for better patient tracking systems.[9]
Nodule pathways carry their own continuum, from ultrasound to aspiration to surveillance or surgery. In a cohort of 188 patients with indeterminate nodules, 56.4% of nodules without nuclear atypia were managed with active surveillance.[4] Of those under surveillance, 95.8% remained stable for at least 24 months.[4] By contrast, 89.1% of nodules with nuclear atypia went to surgery, showing how cytology subcategories split patients into very different pathways.[4] Active surveillance is only safe when someone owns the next scan, the reminder and the escalation if a nodule changes.
Procedural care also needs a defined follow-up step. A review of 18 studies with 5168 patients undergoing thermal ablation found a pooled vocal cord palsy rate of 1.4%, mostly transient.[1] Routine post-procedure vocal cord assessment regardless of symptoms was reported in only 2110 patients, or 40.8%.[1] Post-procedure assessment was performed mostly in symptomatic cases.[1] A system that checks only when patients complain will count fewer complications than actually occur. Without a planned check, outcomes are likely underreported.
Figure 3
Why the pathway breaks
People
- Endocrinology capacity too small for referral volume
- Limited time for counseling in primary care
- Variable expertise in ultrasound and cytology reading
Process
- No owner for repeat testing after an abnormal result
- Referrals sent for questions that advice could answer
- Surveillance scans not scheduled at the decision point
Technology
- Reflex and first-line test rules that generate low-yield results
- No tracking system for patients under surveillance
- Laboratory comments that do not change decisions
Environment
- Rural distance from ultrasound and specialist care
- Regional variation in specialty access
- High overall testing volume in primary care
Policy
- No agreed criteria for advice-only consultation
- Indeterminate nodules managed as one risk group
- Prenatal thyroid monitoring not built into pregnancy pathways
Measurement
- Low-value testing not tracked at practice level
- Repeat-testing intervals not compared with guidance
- Referral and attendance rates not stratified by population
Unranked qualitative cause-and-effect diagram for the outcome in the box: Thyroid tests are ordered without clear value, and abnormal results, nodules and referrals are not followed through on time Causes are assembled from the cited literature [3], [5], [6], [7], [8], [9], [10], [11], [13], [14], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Endocrinology capacity too small for referral volume; Limited time for counseling in primary care; Variable expertise in ultrasound and cytology reading |
| Process | No owner for repeat testing after an abnormal result; Referrals sent for questions that advice could answer; Surveillance scans not scheduled at the decision point |
| Technology | Reflex and first-line test rules that generate low-yield results; No tracking system for patients under surveillance; Laboratory comments that do not change decisions |
| Environment | Rural distance from ultrasound and specialist care; Regional variation in specialty access; High overall testing volume in primary care |
| Policy | No agreed criteria for advice-only consultation; Indeterminate nodules managed as one risk group; Prenatal thyroid monitoring not built into pregnancy pathways |
| Measurement | Low-value testing not tracked at practice level; Repeat-testing intervals not compared with guidance; Referral and attendance rates not stratified by population |
Access
Shortening the path to the right specialist at the right time
Access to endocrinology is a recurring constraint. In a nationally representative U.S. panel of 2,137 adults, a specialist referral had been recommended for 1,391 respondents, or 65%.[14] About 28% of the population experienced a barrier accessing a specialist for themselves or a family member.[14] Differences were observed across census regions and sociodemographic groups.[14] The study covered oncology, neurology, ophthalmology, endocrinology and other specialties, so endocrine access sits within a wider specialty bottleneck.[14]
Referral design can change wait times. A quality improvement pilot screened patients referred to endocrinology for primary hyperparathyroidism and triaged eligible patients directly to endocrine surgery.[10] Of 134 patients, 65 (48.5%) were routed to endocrine surgery.[10] The mean time from referral to appointment was 28 days for endocrine surgery, compared with 118 days for endocrinology.[10] Of those routed to surgery, 61 of 65 (93.8%) were seen, compared with 60 of 69 (87.0%) referred to endocrinology.[10] The authors reported that the program also decreased the burden of care for endocrinology.[10]
Not every referral needs a visit. Two academic endocrinology divisions used formal consensus methods to identify referral scenarios suitable for advice-only electronic consultation.[11] At the first site, consensus was reached on 45 of 58 scenarios (78%), and at the second on 48 (83%).[11] Consensus was defined as at least 70% agreement with fewer than 20% disagreement.[11] Major discordance between sites occurred for only 2 items.[11] A shared list of advice-only scenarios can protect in-person capacity for complex thyroid and nodule care.
Referral volume itself needs management. Across 1,063,646 primary care visits in Singapore in 2023, 19.8% resulted in a referral to tertiary care, with a 76.0% attendance rate.[5] Referrals peaked among patients aged 60 to 70 years.[5] The authors highlighted variation in referral rates, patterns and wait times across clinics.[5] Systems that do not see referral and attendance rates by clinic cannot target education or redesign effectively.
Telehealth is part of the access picture. Its association with fewer low-value thyroid tests suggests that heavier virtual care use does not necessarily mean more wasteful thyroid testing.[13] Leaders should still monitor whether virtual pathways complete the follow-up tests and nodule imaging that patients need. Those checks are easy to overlook when a visit ends on a screen rather than at a front desk where follow-up can be booked.
Executive guidance · System route
Map the path from first contact to verified follow-through.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Support longitudinal navigation
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Support longitudinal navigation
Make entry points, education, service ownership, transitions, and follow-through visible across the locally defined route without prescribing care.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Support longitudinal navigation | Make entry points, education, service ownership, transitions, and follow-through visible across the locally defined route without prescribing care. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Who gets referred, tested and followed up
Equity in thyroid care is largely about who moves through the pathway. In the Singapore referral study, male patients had lower odds of referral, with an odds ratio of 0.88.[5] Malay patients also had lower odds of referral than Chinese patients, with an odds ratio of 0.71.[5] Variation across clinics was also significant, which suggests that local practice patterns play a role.[5] Those differences may reflect need, preference or bias, and only local review can tell them apart.
Specialty access barriers differ by region and population. In the U.S. panel study, 23.0% of respondents were rural dwellers, and difficulty accessing specialty care differed by sociodemographic group.[14] The authors noted that the number of referrals, insurance and other barriers can compound one another.[14] For thyroid care, that means rural and underinsured patients may face longer routes to ultrasound, aspiration and endocrinology.
Sex differences appear in treatment patterns as well as referral. In the hypothyroidism population record, the median levothyroxine dose was higher in men than women in every age decade.[7] The highest median doses were at age 50 to 59 years: 107 mcg per day in men and 93 mcg per day in women.[7] Measures that treat all patients as one group may hide those patterns. Treatment monitoring should be reviewed by sex and age, not only in aggregate.
Pregnant patients are a priority population for equity review because timing matters. Almost half of pregnant women with known hypothyroidism in the Catalonian study had no first-trimester TSH evaluation.[8] Health systems should stratify prenatal thyroid monitoring by insurance, language and site to find where the gap is largest. Among those tested, more than two-thirds had TSH outside the target range.[8] Prenatal pathways serving patients who face language or cost barriers may need targeted outreach and reminders.
Trust depends on consistent explanations. Patients with indeterminate nodules face risk estimates that change with classification.[3] In one surgical cohort, malignancy risk fell from 15.6% to 12.5% for lower-risk indeterminate nodules after excluding a reclassified noninvasive tumor type.[3] Clinicians need shared language so that patients across sites hear the same, accurate account of their options. Interpreter access and plain-language materials help ensure that surveillance is a shared decision rather than a confusing delay.

Human infrastructure
Laboratories, primary care and endocrine teams carry the load
Thyroid care runs on a broad workforce: primary care clinicians, laboratory scientists, sonographers, cytopathologists, endocrinologists, surgeons and nurses. Many of the gaps in the evidence are workflow gaps, not knowledge gaps. When a result goes unactioned, the usual reasons are unclear ownership, missing reminders or insufficient time. Workforce planning for thyroid care is therefore as much about workflow design as about headcount.
Laboratory decisions shape everyone else’s workload. A comparison of two NHS laboratories, one adding interpretive comments to thyroid results and one not, covered 121 961 and 247 639 tests respectively.[6] The two trusts served 18 242 and 31 655 people with treated hypothyroidism.[6] The proportion of TSH results within the reference interval was similar, at 83.4% and 83.9%.[6] Repeat-testing intervals differed from national guidance in both trusts.[6] Adding comments did not change TSH results or retesting intervals in a clinically meaningful way.[6] Laboratory time may be better spent on test menus and follow-up rules.
Primary care documentation and counseling need support. In the Malaysian hyperthyroidism study, documentation of etiology reached 52.4% and treatment counseling only 28.7%.[9] Side effect counseling was documented in just 11.9%.[9] Those figures point to the need for templates, protected time and team roles such as nurses or pharmacists who can carry structured education. Structured education can also explain why repeat testing matters, which supports the monitoring gaps described earlier. Pharmacists can review dosing and adherence for patients whose results remain out of range.
Cytopathology and ultrasound expertise drive nodule decisions. In one cohort, malignancy rates were 32.3% for Bethesda III, 63.2% for Bethesda IV and 77.8% for Bethesda V nodules.[2] Hypoechoic and isoechoic nodules and nuclear clefts on cytology were independent predictors of malignancy.[2] In a single-center surgical cohort, cytology-histology agreement was substantial, with a kappa of 0.72.[3] Those results depend on skilled readers and consistent reporting. Variation in reading and reporting across sites can translate directly into variation in surgery rates.
Endocrinologists are the scarcest resource in many systems. Triage that sends suitable patients directly to surgery or advice-only consultation can protect their time.[10][11] Leaders should treat endocrinology capacity as a shared system asset, review it alongside imaging and laboratory capacity, and design referral rules to match it. Consensus lists of advice-only scenarios help primary care clinicians send the right patients.[11] Those tools also reduce the back-and-forth that consumes scheduling and nursing time.
Executive guidance · Operating dashboard
Measure whether the operating route works as intended.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Longitudinal ownership
Can people and teams see who owns the next step across a route that may involve repeated contacts?
- Candidate local measure
- Locally defined repeated contacts, aged work, transition acceptance, unresolved routes, and experience feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Longitudinal ownership | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Keep work owned when it crosses a boundary.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Record the next owner, status, and approved follow-through route so responsibility does not disappear between contacts.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Ask questions that connect intent, ownership, and results.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Longitudinal ownership | Can people and teams see who owns the next step across a route that may involve repeated contacts? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable thyroid testing and follow-up pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Thyroid test menu and reflex rules reviewed for value | Low-yield results drive unnecessary investigation | Laboratory medical director with primary care lead | Low-value thyroid tests per 1000 attributed patients |
| Abnormal result follow-up assigned to a named owner | Repeat tests and treatment changes are missed | Ambulatory quality lead | Share of abnormal results with a repeat test or action within the defined interval |
| Prenatal thyroid monitoring built into pregnancy intake | Early pregnancy testing gaps go unnoticed | Women’s health service line leader | Share of pregnancies with known hypothyroidism tested in the first trimester |
| Nodule surveillance registry with scheduled next scan | Patients under active surveillance are lost | Endocrinology and radiology leads | Share of surveillance patients with a scan completed on schedule |
| Referral triage with direct routing and advice-only options | Long waits for endocrinology | Specialty access director | Days from referral to first appointment or advice |
| Stratified referral and follow-up reporting | Disparities by sex, ethnicity or rurality remain hidden | Chief quality officer | Quarterly stratified report reviewed by a board committee |
Control points derived from the cited evidence [4], [5], [7], [8], [10], [11], [13] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating proportion, uncertainty and next steps
Thyroid awareness messages can raise demand for tests that add little value. Public communication should therefore emphasize appropriate testing, reliable follow-up and clear next steps rather than broad calls to get checked. Messages that promise a quick test can create follow-up work that the system is not ready to absorb. A better message tells people when testing is useful and what happens after a result.
Patients need honest explanations of uncertainty. Indeterminate nodules carry very different risks: in one cohort, malignancy risk was 15.6% for TIR3A nodules and 48.7% for TIR3B nodules.[3] The authors described a noninvasive tumor reclassification as an important source of potential overtreatment.[3] Communication that explains why surveillance is sometimes the safer choice can build trust in a measured approach. Plain-language explanations of risk categories, reviewed with patients, can make those conversations more consistent. Consistency across sites also matters, because patients compare what they hear.
Subclinical results call for similar care. Most patients with subclinical hypothyroidism in one clinic regressed to a normal state without treatment in the short term.[12] Patient materials can explain why a repeat test is often the next step and how the organization will make sure it happens. In that clinic, 21.2% remained subclinically hypothyroid at three months, so follow-up still matters.[12]
Procedure counseling should be grounded in standardized data. The thermal ablation review found that permanent vocal cord palsy was rare, at 0.05%.[1] It also found that objective pre-procedure vocal cord assessment was reported in only 2054 patients, or 39.7%.[1] The authors called for routine evaluation and standardized reporting to support accurate patient counseling.[1] Patients weighing surgery, ablation and surveillance deserve information drawn from consistent measurement.
Communication with clinicians matters as much as public messaging. Interpretive comments on laboratory reports did not meaningfully change TSH results or retesting intervals.[6] Clinician-facing communication may work better through order sets, referral criteria and feedback on testing patterns. Clear, consistent messages to both patients and clinicians make the thyroid pathway easier to use and easier to trust. Public reports can describe what the organization measures, such as follow-up of abnormal results and referral wait times. Sharing that progress shows that awareness is backed by reliable operations. The goal for this observance is simple to state: fewer tests that add little, and no abnormal result, nodule or referral left without an owner.

Executive guidance · 90-day plan
Move from listening to a verified improvement in 90 days.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Thyroid Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Review one repeated-contact or cross-service route and correct a verified ownership or information gap.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Thyroid Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Review one repeated-contact or cross-service route and correct a verified ownership or information gap. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Carry one accountable improvement beyond the campaign window.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Listen to the people closest to the route, assign one barrier, and verify the change.
Executive action kit · Month observance
Turn Thyroid Awareness Month into accountable action.
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, longitudinal ownership, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review language, transportation, affordability, food access, digital access, disability, and geographic availability.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, caregivers, primary care, specialty services, pharmacy, and community partners. Find one a confusing entry point, fragmented follow-through, or an unresolved navigation need, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Support longitudinal navigation
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined repeated contacts, aged work, transition acceptance, unresolved routes, and experience feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During Thyroid Awareness Month, our organization will connect awareness with a practical review of the information, access, longitudinal ownership, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Thyroid Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Mouratidou S, Dabab N, Habib A, Seif‐Elnasr M, Rovira A, Simo R. Voice Outcomes Following Thermal Ablation for Thyroid Nodules: A Systematic Review. Otolaryngology–Head and Neck Surgery. 2026:ohn.70502. https://doi.org/10.1002/ohn.70502
- 2.Santos GGD, Tirapani WM, Riguetto CM, Barreto IS, Zantut-Wittmann DE. Importance of clinical, ultrasound and cytological characteristics in predicting malignancy in thyroid nodules with indeterminate cytology. Annals of Medicine. 2026;58(1):2654901. https://doi.org/10.1080/07853890.2026.2654901
- 3.De Luca P, Chiappino G, de Campora L, Sambito A, Camaioni A, Viti C. Risk Stratification of Indeterminate Thyroid Nodules (TIR3A vs. TIR3B): Impact of NIFTP Reclassification in a Surgical Cohort. Cancers. 2026;18(9):1481. https://doi.org/10.3390/cancers18091481
- 4.Mouratidou S, Yanni M, Rovira A, Arora A, Jeannon JP, Munonyara MT, et al. The role of cytological subcategorization in indeterminate thyroid nodules: Optimizing management strategies by refining malignancy risk stratification. European Archives of Oto-Rhino-Laryngology. 2026;283(9):5949-5957. https://doi.org/10.1007/s00405-026-10375-w
- 5.Koh SWC, Huang JYX, Lam J, Low SH, Goh JC, Ji G, et al. Factors and determinants of primary care to tertiary care referrals in Singapore: A multi-centre analysis using artificial intelligence-powered large language models. PLOS ONE. 2026;21(2):e0338085. https://doi.org/10.1371/journal.pone.0338085
- 6.Mallorie A, James T, deFonseka S, Weerasinghe G, Green D, Shine B. Adding interpretative comments to results of thyroid function tests from patients on thyroxine replacement does not improve management. Journal of Clinical Pathology. 2025:jcp-2025-210174. https://doi.org/10.1136/jcp-2025-210174
- 7.Heald AH, Premawardhana LD, Taylor PN, Bahl S, Okosieme OE, Fryer AA, et al. Evaluating the Link Between Thyroid Function Test Results and Levothyroxine Dose in the Management of Hypothyroidism: Can We Improve Dosing Regimes?. Clinical Endocrinology. 2025;104(4):372-385. https://doi.org/10.1111/cen.70074
- 8.Tena Vivó G, Cunillera Puértolas O, Albareda Riera M, Parellada Esquius N, Isidro Albaladejo M, Rodríguez Palomar G, et al. Hypothyroidism monitoring and control during the first trimester of pregnancy in Catalonia. Frontiers in Endocrinology. 2025;16:1445977. https://doi.org/10.3389/fendo.2025.1445977
- 9.Jamaluddin J, Zainal-Abidin ANI, Mohamed Kamel MA, Nik Abdul Kadir NA, Mohd Yusri MY, Ibrahim N, et al. Assessment and outcome of the management of hyperthyroidism in Malaysian primary care clinics: A national multicentre study. Journal of Diabetes & Metabolic Disorders. 2025;24(2):204. https://doi.org/10.1007/s40200-025-01716-3
- 10.Sheu NO, Soelling SJ, Awtry JA, Mahvi DA, Nehs MA, Doherty GM, et al. Streamlining Health Care Access for Patients With Primary Hyperparathyroidism: A Quality Improvement Pilot Program. Journal of Surgical Research. 2025;313:148-152. https://doi.org/10.1016/j.jss.2025.06.010
- 11.Lochnan H, Mukerji G, Keely E, Tran C, Humphrey-Murto S. Triage to Advice Only for Referring Providers: A Pilot Project Using Formal Consensus Methods to Establish Appropriate Patients for Electronic Consultations. AACE Endocrinology and Diabetes. 2025;12(4):367-373. https://doi.org/10.1016/j.aed.2025.08.002
- 12.Violante-Ortiz R, Fernández-Ordóñez N, Narvaez Gallifa E, Hernandez Molina EE, Guerra Cardenas JE, Reyna-Beltrán E, et al. Progression of Subclinical Hypothyroidism in a Mexican Public Hospital Population: A Retrospective Cohort Study. Cureus. 2025. https://doi.org/10.7759/cureus.82923
- 13.Liu T, Zhu Z, Thompson MP, McCullough JS, Hou H, Chang CH, et al. Primary Care Practice Telehealth Use and Low-Value Care Services. JAMA Network Open. 2024;7(11):e2445436. https://doi.org/10.1001/jamanetworkopen.2024.45436
- 14.Schuldt R, Jinnett K. Barriers accessing specialty care in the United States: a patient perspective. BMC Health Services Research. 2024;24(1):1549. https://doi.org/10.1186/s12913-024-11921-0
- 15.Evans C, Jacob J, Rodham A, Gill M, Parry L, Dodd A, et al. Current utility of first‐line FT4 and TSH in screening for central hypothyroidism. Clinical Endocrinology. 2024;101(1):78-84. https://doi.org/10.1111/cen.15068
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Thyroid testing volume and control on levothyroxine | [7] | 2025 | Current evidence | Single city-wide population record in England; reference ranges may not fit treated patients. |
| Yield of first-line free thyroxine testing for central hypothyroidism | [15] | 2024 | Current evidence | Welsh laboratory data; detection varied by assay. |
| Telehealth use and low-value thyroid testing | [13] | 2024 | Current evidence | Observational Medicare fee-for-service claims in Michigan. |
| Natural course of subclinical hypothyroidism | [12] | 2025 | Current evidence | Single public hospital clinic; three-month follow-up. |
| First-trimester thyroid monitoring in pregnancy | [8] | 2025 | Continuum of care | Primary care records in Catalonia from 2014 to 2016. |
| Hyperthyroidism monitoring, documentation and counseling in primary care | [9] | 2025 | Continuum of care | Retrospective record review of 143 patients in one country. |
| Active surveillance and risk stratification of indeterminate nodules | [2] [3] [4] | 2026 | Continuum of care | Retrospective, mostly surgically selected cohorts from single or few centers. |
| Voice outcomes and assessment after thermal ablation | [1] | 2026 | Continuum of care | Heterogeneous studies with nonstandard voice assessment. |
| Barriers to specialty care in the United States | [14] | 2024 | Access | Self-reported survey data from 2021 across several specialties. |
| Direct triage and advice-only consultation to reduce endocrine wait times | [10] [11] | 2025 | Access | Single-center pilot for hyperparathyroidism; consensus study at two academic sites. |
| Referral rates, attendance and disparities | [5] | 2026 | Equity and trust | Seven primary care clinics in Singapore in 2023. |
| Interpretive laboratory comments and management | [6] | 2025 | Human infrastructure | Two NHS trusts; comparison of policies, not a randomized test. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

